Vaccine Vaxirab N along with Rabimabs for the treatment of Rabies.

Phase 3

• Conditions: Health Condition 1: null- Rabies InfectionHealth Condition 2: A829- Rabies, unspecified

• Registration Number: CTRI/2017/07/009038
• Lead Sponsor: Cadila Healthcare Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Male and Female patients aged 5 years or more than 5 years.

2.WHO Category III exposure(s) by a suspected rabid animal.

3.Have documented informed consent from individuals, the childâ??s parent(s) or legal guardian(s) and assent from the child if appropriate.

4.Free of obvious health problems as determined by history and examination.

5.If female, not pregnant or lactating at the time of enrolment and not planning pregnancy during the vaccination period.

6.Male subjects must be agree to use at least one effective contraceptive method throughout the entire duration of the study.

Exclusion Criteria

1.Pregnant and lactating women.

2.Patient has received any dose of rabies vaccines / rabies immunoglobulin in the past.

3.Allergic to any of the vaccine component / human rabies immunoglobulin components.

4.Chronic administration of immunosuppressants or other immune-modifying agents.

5.Unable to follow all required study procedures for the whole period of the study.

6.Acute febrile illness or acute infectious disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified